Incyte Archives -

Incyte’s Opzelura cream has become the first medical treatment approved to re-pigment the skin of people with vitiligo

FDA clears Incyte’s Opzelura as first vitiligo therapy

https://pharmaphorum.com/news/fda-clears-incytes-opzelura-as-first-vitiligo-therapy/

Market Access/ News/ News/ News/ Sales and Marketing

Lilly’s Olumiant okayed in alopecia, with Pfizer, Concert in hot pursuit

Phil Taylor alopecia, Concert Pharma, Eli Lilly, Incyte, JAK inhibitor, Olumiant, Pfizer 0 Comment

Eli Lilly and Incyte’s Olumiant has secured the first FDA approval for a systemic drug to treat alopecia

Lilly’s Olumiant okayed in alopecia, with Pfizer, Concert in hot pursuit

https://pharmaphorum.com/news/lillys-olumiant-okayed-in-alopecia-with-pfizer-concert-in-hot-pursuit/

News/ News/ R&D

Olumiant benefits additive to other drugs in severe COVID patients

Phil Taylor Actemra, coronavirus, COVID-19, Eli Lilly, Gilead Sciences, Incyte, JAK inhibitor, Olumiant, Roche, Veklury 0 Comment

Eli Lilly and Incyte’s JAK inhibitor Olumiant reduced the risk of death by 13% in hospitalised COVID-19 patients

Olumiant benefits additive to other drugs in severe COVID patients

https://pharmaphorum.com/news/olumiant-benefits-additive-to-other-drugs-in-severe-covid-patients/

Market Access/ News/ News

FDA sets April date for verdict on Incyte’s vitiligo drug

Phil Taylor dermatology, fda, Incyte, Opzelura, regulatory, vitiligo 0 Comment

Incyte could be a few month away from a second FDA approval for its Opzelura cream that would

FDA sets April date for verdict on Incyte’s vitiligo drug

https://pharmaphorum.com/news/fda-sets-april-date-for-verdict-on-incytes-vitiligo-drug/

Market Access/ News/ News

Incyte leads JAK push into eczema as FDA clears Opzelura cream

Phil Taylor dermatology, fda, Immunology and inflammation, Incyte, JAK inhibitor, Opzelura, regulatory approval 0 Comment

The FDA has approved Incyte’s Opzelura cream for atopic dermatitis, commonly called eczema, becoming the first and only

Incyte leads JAK push into eczema as FDA clears Opzelura cream

https://pharmaphorum.com/news/incyte-leads-jak-push-into-eczema-as-fda-clears-opzelura-cream/

News/ News/ Oncology

Incyte, MorphoSys’ CAR-T rival tafasitamab approved in EU

Phil Taylor CAR-T therapies, EU, Incyte, MorphoSys, non-Hodgkin lymphoma, regulatory approval, tafasitamab 0 Comment

Incyte and MorphoSys’ antibody therapy tafasitamab has been approved in Europe, promising to provide a more convenient alternative

Incyte, MorphoSys’ CAR-T rival tafasitamab approved in EU

https://pharmaphorum.com/news/incyte-morphosys-car-t-rival-tafasitamab-approved-in-eu/

News/ News/ R&D

Lilly has a bad hair day as Pfizer rival hits the mark in alopecia

Phil Taylor alopecia, autoimmune disease, Concert Pharma, Eli Lilly, Incyte, JAK inhibitor, Pfizer 0 Comment

Eli Lilly and Incyte have another rival in the rear-view mirror for Olumiant in alopecia areata after Pfizer

Lilly has a bad hair day as Pfizer rival hits the mark in alopecia

https://pharmaphorum.com/news/lilly-has-a-bad-hair-day-as-pfizer-rival-hits-the-mark-in-alopecia/

Market Access/ News/ News

NICE changes its mind on rare bile duct cancer drug from Incyte

Phil Taylor cholangiocarcinoma, HEOR, Incyte, NICE, Oncology, Pemazyre, pemigatinib, targeted oncology 0 Comment

Incyte’s Pemazyre has become the first targeted therapy available for NHS patients with cholangiocarcinoma or bile duct cancer,

NICE changes its mind on rare bile duct cancer drug from Incyte

https://pharmaphorum.com/news/nice-changes-its-mind-on-rare-bile-duct-cancer-drug-from-incyte/

News/ News/ R&D

Incyte preps second filing for ruxolitinib cream after vitiligo trial win

Richard Staines dermatology, Incyte, ruxolitinib, vitiligo 0 Comment

Incyte has made further progress with its ruxolitinib cream, notching up a phase 3 trial showing it can

Incyte preps second filing for ruxolitinib cream after vitiligo trial win

https://pharmaphorum.com/news/incyte-preps-second-filing-for-ruxolitinib-cream-after-vitiligo-trial-win/

Trending

Incyte

Login